Abstract
The p16 protein, a cyclin-dependent kinase inhibitor, has been found to be significantly increased in patients with non-small cell lung cancer (NSCLC). Our previous study demonstrated that circulating autoantibody to p16 protein-derived peptides (anti-p16) may be a useful biomarker with prognostic values for NSCLC. Variations of humoral immune response to tumor related antigen can partly explain that normal tissue tolerance to radiation therapy varies by individual. This study aimed to examine the association between the levels of circulating anti-p16 and radiation pneumonitis (RP) in patients with NSCLC treated with radiation therapy (RT).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Radiation Oncology*Biology*Physics
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
